Continued losses and accumulated deficit of 95 billion won, capital improvement via 35.6 billion hybrid securities


  • Consolidated 2025 revenue of 2.85 billion won (up 12.6% from 2.53 billion), operating loss of 8.38 billion (vs 8.62 billion), net loss attributable to controlling interest of 15.71 billion (vs 10.91 billion); accumulated deficit of 95.04 billion
  • Cash and cash equivalents fell sharply to 80 million won from 1.26 billion; negative operating cash flow of 5.18 billion, worsening liquidity risk
  • Issuance of 35.6 billion won hybrid securities to (Yoo) Human Data increased total equity to 28.62 billion, improving debt ratio to 55.75% (from 255.28%)
  • Going concern uncertainty noted; mitigation plans include sale of Daechi-dong property (approx. 30 billion won) and investment in new businesses such as data centers
  • Shareholder meeting agenda: amendment of articles (increase authorized shares to 300 million, CB limit to 400 billion, etc.), election of 5 inside directors (including CEO Kang Seong-min), approval of director/auditor compensation limits
  • Subsequent events: borrowing of 5 billion from related party, completion of 3.21 billion capital increase via third-party allotment to RealityGen, and registration of property transfer
ADVERTISEMENT (250px+)

KOSDAQ Filing Information


  • Filing: Notice of Convocation of Shareholders' Meeting
  • Company: PeopleBio (304840)
  • Submission: PeopleBio, Inc.
  • Receipt: 04-27-2026